Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

Both 6-month trials were randomized, controlled studies that evaluated PER-001 delivered in a slow-release, dissolvable ...

HealthDay News — For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased risk for incident neovascular age-related macular ...

Both Eli Lilly and Novartis once had their PD-1 inhibitor dreams shattered, and both know the VEGF realm.

Amarnath is senior and corresponding author of the researchers’ published paper in Nature Immunology, titled “ PD-1 receptor deficiency enhances CD30 + T reg cell function in melanoma.” ...

About IBI363 (First-in-class PD-1/IL-2α-bias bispecific antibody fusion protein) IBI363 is a first-in-class PD-1/IL-2 α-bias bispecific antibody fusion protein independently developed by Innovent ...

Researchers trace the evolutionary history of the PD-1 immune checkpoint system across jawed vertebrates, uncovering conserved features with potential relevance for cancer immunotherapy.

SHP-2L is expected to bind PD-1 similar to SHP-2. This comparative analysis of PD-1 and its interacting molecules across jawed vertebrates highlights conserved immune checkpoint features while ...

PD-1 blockade conferred benefit to certain women with surgically resectable endometrial cancer, findings presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer showed.

The PD-1 receptor, a major immune checkpoint inhibitor whose signaling is the target of multiple blockbuster anticancer drugs, differs functionally between rodents and humans in previously unknown ...